These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 17230422)
1. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. Cruz A; Rainey PM; Herwaldt BL; Stagni G; Palacios R; Trujillo R; Saravia NG J Infect Dis; 2007 Feb; 195(4):602-8. PubMed ID: 17230422 [TBL] [Abstract][Full Text] [Related]
2. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655 [TBL] [Abstract][Full Text] [Related]
3. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate. Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235 [TBL] [Abstract][Full Text] [Related]
4. Allopurinol in the treatment of American cutaneous leishmaniasis. Martinez S; Marr JJ N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379 [TBL] [Abstract][Full Text] [Related]
5. Effects of fluconazole on the pharmacokinetics and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters. Alnaim L; Abou Alsoud N; Zaghloul I; Al-Jaser M Int J Antimicrob Agents; 2007 Jun; 29(6):728-32. PubMed ID: 17369029 [TBL] [Abstract][Full Text] [Related]
6. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate. Neves DB; Caldas ED; Sampaio RN Trop Med Int Health; 2009 Dec; 14(12):1515-22. PubMed ID: 19954451 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Munir A; Janjua SA; Hussain I Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100 [TBL] [Abstract][Full Text] [Related]
8. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Chulay JD; Fleckenstein L; Smith DH Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611 [TBL] [Abstract][Full Text] [Related]
10. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Momeni AZ; Aminjavaheri M Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780 [TBL] [Abstract][Full Text] [Related]
12. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. Salmanpour R; Handjani F; Nouhpisheh MK J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707 [TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064 [TBL] [Abstract][Full Text] [Related]
14. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate. Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977 [TBL] [Abstract][Full Text] [Related]
15. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Shazad B; Abbaszadeh B; Khamesipour A Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817 [TBL] [Abstract][Full Text] [Related]
16. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Firooz A; Khamesipour A; Ghoorchi MH; Nassiri-Kashani M; Eskandari SE; Khatami A; Hooshmand B; Gorouhi F; Rashighi-Firoozabadi M; Dowlati Y Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206 [TBL] [Abstract][Full Text] [Related]
19. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Oliveira-Neto MP; Schubach A; Mattos M; Gonçalves-Costa SC; Pirmez C Pathol Biol (Paris); 1997 Jun; 45(6):496-9. PubMed ID: 9309267 [TBL] [Abstract][Full Text] [Related]
20. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device. Bogenrieder T; Lehn N; Landthaler M; Stolz W Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]